NewAmsterdam Pharma NAMS
Ownership & positioning
Who holds it, who is betting against it, and where the big money is moving
Short-sale volume as % of daily volume
Large-order net flow, last 20 sessions
Net of large-order buying minus selling, in USD. Over this window: −$18.94M (7 inflow days, 13 outflow days).
Net flow by order size, last 20 sessions
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 53.2% of shares outstanding.
Largest holders
By investor type
Reported short interest has fallen from 10.59% to 10.05% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).
Recent institutional activity
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| FMR | Mutual Fund | 2026/Q3 | +1,777,081 | 10.1% |
| Capital Research | Mutual Fund | 2026/Q3 | +769,602 | 12.3% |
| Barclays PLC | Public Company | 2026/Q3 | +272,337 | 0.2% |
| Morgan Stanley | Public Company | 2026/Q3 | +260,757 | 0.7% |
| Morgan Stanley Investment Management Inc. | Mutual Fund | 2026/Q3 | +260,757 | 0.7% |
| American Century Investment Management | Mutual Fund | 2026/Q3 | +180,590 | 0.7% |
| Mizuho Financial Group, Inc. | Public Company | 2026/Q3 | +158,621 | 0.3% |
| Frazier Life Sciences Management, LP | VC/PE Fund | 2026/Q3 | +850,000 | 15.8% |
| Orbis Investment Management Limited | Mutual Fund | 2026/Q3 | +1,747,627 | 1.5% |
| FMR | Mutual Fund | 2026/Q3 | +1,573,852 | 8.6% |
| Capital Research | Mutual Fund | 2026/Q3 | +1,403,887 | 11.7% |
| T. Rowe Price Group, Inc. | Mutual Fund | 2026/Q3 | +1,167,357 | 1.0% |
| Maverick Capital, Ltd. | Hedge Fund | 2026/Q3 | +1,081,400 | 2.7% |
| Susquehanna International Group, LLP | Private Company | 2026/Q3 | +736,502 | 0.6% |
| ODDO BHF Asset Management SAS | Mutual Fund | 2026/Q3 | +619,793 | 0.5% |
Institutional buy/sell activity by reporting period, largest moves first.
Insider transactions
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 29 Sep 2026 | Johannes Jacob Kastelein | Founder, Chief Scientific Officer, Member of Executive Board & Director | Derivative Exercise and Sale | -50,246 | $25.03 | 74,636 |
| 13 Sep 2026 | Michael Davidson | Chief Executive Officer | Open Market Acquisition | +10,000 | $22.65 | 915,285 |
| 3 Sep 2026 | John Smither | Independent Director | Open Market Disposition | -1,600 | $25.32 | 720 |
| 31 Aug 2026 | Robert Gunning | Principal Accounting Officer, VP & Controller | Other Acquisition | +3,200 | – | 3,200 |
| 31 Aug 2026 | Robert Gunning | Principal Accounting Officer, VP & Controller | Other Derivative Acquisition | +14,000 | $24.92 | 14,000 |
| 24 Aug 2026 | Johannes Jacob Kastelein | Founder, Chief Scientific Officer, Member of Executive Board & Director | Intent to Sell (Form 144) | -250,000 | – | – |
| 23 Aug 2026 | Johannes Jacob Kastelein | Founder, Chief Scientific Officer, Member of Executive Board & Director | Derivative Exercise and Sale | -125,000 | $26.91 | 74,636 |
| 19 Jul 2026 | Louise Kooij | Former Chief Accounting Officer | Derivative Exercise and Sale | -105,000 | $31.71 | 2,353 |
| 21 Jun 2026 | Louise Kooij | Former Chief Accounting Officer | Derivative Exercise and Sale | -40,000 | $30.73 | 2,353 |
| 25 May 2026 | Louise Kooij | Former Chief Accounting Officer | Derivative Exercise and Sale | -65,000 | $35.69 | 2,353 |
| 10 Mar 2026 | Louis Lange | Independent Non-Executive Director | Open Market Disposition | -44,619 | $31.23 | 2,320 |
| 8 Mar 2026 | Louis Lange | Independent Non-Executive Director | Derivative Exercise and Retained | +44,619 | $11.50 | 46,939 |
| 8 Mar 2026 | Johannes Jacob Kastelein | Founder, Chief Scientific Officer, Member of Executive Board & Director | Derivative Exercise and Sale | -300,000 | $30.32 | 74,635 |
| 5 Mar 2026 | Louis Lange | Independent Non-Executive Director | Open Market Disposition | -28,186 | $29.41 | 46,939 |
| 1 Mar 2026 | Michael Davidson | Chief Executive Officer | Derivative Exercise and Sale | -443,707 | $33.25 | 296,506 |
| 1 Mar 2026 | Johannes Jacob Kastelein | Founder, Chief Scientific Officer, Member of Executive Board & Director | Intent to Sell (Form 144) | -300,000 | $31.18 | – |
| 25 Feb 2026 | Michael Davidson | Chief Executive Officer | Derivative Exercise and Sale | -306,293 | $36.68 | 296,506 |
| 23 Feb 2026 | Michael Davidson | Chief Executive Officer | Intent to Sell (Form 144) | -750,000 | $36.17 | – |
| 19 Feb 2026 | Johannes Jacob Kastelein | Founder, Chief Scientific Officer, Member of Executive Board & Director | Open Market Disposition | -45,481 | $35.46 | 74,635 |
| 27 Jan 2026 | Louise Kooij | Former Chief Accounting Officer | Derivative Exercise and Sale | -72,428 | $32.62 | 2,353 |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
Short interest, by report
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 30 Oct 2026 | 12,009,626 | 10.0% | 8.3 |
| 15 Oct 2026 | 14,110,048 | 11.8% | 10.6 |
| 30 Sep 2026 | 19,045,378 | 15.9% | 9.4 |
| 15 Sep 2026 | 15,660,444 | 13.1% | 9.9 |
| 31 Aug 2026 | 13,392,021 | 11.2% | 13.4 |
| 14 Aug 2026 | 12,654,106 | 10.6% | 9.9 |
No comments yet — be the first to weigh in on NAMS.
Sign in to join the discussion.